Effects of X Box Kinect 360 in Alzheimer's Disease (AD Alzheimer')
23. juni 2026 opdateret af: Ziauddin University
Effect of 3D Kinect Games With Google Cardboard on Motor Control, Cognition, and Quality of Life in Mild to Moderate Alzheimer's Patient
Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia that accounting for 60% to 80% of all cases (Better, et al., 2023).
According to world health organization (WHO), more than 55 million people globally live with dementia, and this number is expected to rise to 78 million by 2023 and 139 million by 2050 (WHO, 2021).
Studieoversigt
Status
Ikke rekrutterer endnu
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
In the line with global epidemiology trend, the prevalence of AD is also rising at the regional level.
In the United States, approximately 6.2 million individual aged 65 and older recently living with AD, and this figured is expected to reach 13.8 million by 2060 (Doher et al., 2023).
Similarly, in Europe, the prevalence of AD is estimated at 5.05%, with a notably higher incidence in women (7.13%) as compared to men (3.31%) (Niu et al., 2017).
Moreover, Asia alone has a higher prevalence of dementia patients than both America and Europe.
A study conducted in tertiary care centers in Karachi showed that 63% of dementia patients had AD (Siddiqui et al., 2018).
Undersøgelsestype
Interventionel
Tilmelding (Anslået)
38
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiekontakt
- Navn: Silvia Peter William, Mphil
- Telefonnummer: 5 021-36629251
- E-mail: williamsilviapeter@gmail.com
Studiesteder
-
-
Sindhi
-
Karachi, Sindhi, Pakistan
- Ziauddin University
-
Kontakt:
- Silvia Peter William, Mphil
- Telefonnummer: 5 021-36629251
- E-mail: williamsilviapeter@gmail.com
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Ingen
Beskrivelse
Inclusion Criteria
- Alzheimer's disease of age between 50-85 years.
- Diagnosed AD stage Mild to Moderate.
Exclusion Criteria:
- Undiagnosed AD patients.
- Mental or neurological conditions like schizophrenia, Parkinson's, or stroke.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Støttende pleje
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Arms 1
Arm Description: Game-Based Rehabilitation received total 30sessions, 30 minutes/session, 5 times/week for total 6 weeks.
|
Experimental group will receive X boc kinect 360 bomb such as match makers, traffic control, mouse mayhem, strike a pose, pizza catch, flag frenzy, follow the arrow for 30 minutes for five days a week, for six weeks.
|
|
Placebo komparator: Arm 2
Arm Description: Conventional Rehabilitation received total 30 sessions, 30 minutes/session, 5 times/week for total 6 weeks.
|
The intervention will run for 30 minutes (excluding rest period), five days a week, for six weeks (Deng, et al., 2025).
The patients will take 1-2 minutes rest after 5 minutes of activity.
Rest periods of 1-2 minutes after every 5 minutes of activity.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Cognition
Tidsramme: Baseline
|
Cognitive function will be assessed through among mild to moderate AD patients where low values indicate decrease in cognitive ability.
|
Baseline
|
|
Cognition
Tidsramme: After 6 week of Intervention
|
Cognitive function will be assessed through Mini- Cog among Mild to Moderate AD patients where low values indicate decrease cognitive function
|
After 6 week of Intervention
|
|
Motor Function
Tidsramme: Baseline
|
Motor function will be assessed using the Timed Up and Go (TUG) Test among patients with mild to moderate Alzheimer's disease (AD), where higher scores (longer completion times) indicate poorer functional mobility
|
Baseline
|
|
Motor Function
Tidsramme: After 6 week of intervention
|
Motor function will be assessed using the Timed Up and Go (TUG) Test among patients with mild to moderate Alzheimer's disease (AD), where higher scores (longer completion times) indicate functional mobility
|
After 6 week of intervention
|
|
Quality of Life (QOL)
Tidsramme: Baseline
|
Quality of life will be assessed using the Quality of Life in Alzheimer's Disease (QOL-AD) scale among patients with mild to moderate Alzheimer's disease.
Lower scores indicate poorer quality of life, whereas higher scores indicate better perceived quality of life.
|
Baseline
|
|
Quality Of Life (QOL)
Tidsramme: After 6 weeks of Intervention
|
Quality of life will be assessed using the Quality of Life in Alzheimer's Disease (QOL-AD) scale among patients with mild to moderate Alzheimer's disease.
Lower scores indicate poorer quality of life, whereas higher scores indicate better perceived quality of life.
|
After 6 weeks of Intervention
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Efterforskere
- Ledende efterforsker: Silvia Peter William, MPhil, Ziauddin University, Karachi, Sindh, Pakistan
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Generelle publikationer
- Borson S, Scanlan JM, Chen P, Ganguli M. The Mini-Cog as a screen for dementia: validation in a population-based sample. J Am Geriatr Soc. 2003 Oct;51(10):1451-4. doi: 10.1046/j.1532-5415.2003.51465.x.
- Cox KL, Clare L, Cyarto EV, Ellis KA, Etherton-Beer C, Southam J, Ames D, Flicker L, Almeida OP, LoGiudice D, Liew D, Vlaskovsky P, Lautenschlager NT. A Randomized Controlled Trial on the Effects of a 6-Month Home-Based Physical Activity Program with Individual Goal-Setting and Volunteer Mentors on Physical Activity, Adherence, and Physical Fitness in Inactive Older Adults at Risk of Cognitive Decline: The INDIGO Study. J Alzheimers Dis. 2021;84(1):207-226. doi: 10.3233/JAD-210479.
- Cousi C, Igier V, Quintard B. French cross-cultural adaptation and validation of the Quality of Life-Alzheimer's Disease scale in Nursing Homes (QOL-AD NH). Health Qual Life Outcomes. 2021 Sep 15;19(1):219. doi: 10.1186/s12955-021-01853-2.
- Conti Filho CE, Loss LB, Marcolongo-Pereira C, Rossoni Junior JV, Barcelos RM, Chiarelli-Neto O, da Silva BS, Passamani Ambrosio R, Castro FCAQ, Teixeira SF, Mezzomo NJ. Advances in Alzheimer's disease's pharmacological treatment. Front Pharmacol. 2023 Jan 26;14:1101452. doi: 10.3389/fphar.2023.1101452. eCollection 2023.
- Chen C, Homma A, Mok VC, Krishnamoorthy E, Alladi S, Meguro K, Abe K, Dominguez J, Marasigan S, Kandiah N, Kim SY, Lee DY, De Silva HA, Yang YH, Pai MC, Senanarong V, Dash A. Alzheimer's disease with cerebrovascular disease: current status in the Asia-Pacific region. J Intern Med. 2016 Oct;280(4):359-74. doi: 10.1111/joim.12495. Epub 2016 Mar 16.
- Cezar NOC, Ansai JH, de Andrade LP. Home-based multimodal exercise program in older people with Alzheimer disease: Randomized controlled trial protocol. Physiother Res Int. 2021 Apr;26(2):e1899. doi: 10.1002/pri.1899. Epub 2021 Feb 15.
- 2023 Alzheimer's disease facts and figures. Alzheimers Dement. 2023 Apr;19(4):1598-1695. doi: 10.1002/alz.13016. Epub 2023 Mar 14.
- Appel L, Kisonas E, Appel E, Klein J, Bartlett D, Rosenberg J, Smith C. Introducing virtual reality therapy for inpatients with dementia admitted to an acute care hospital: learnings from a pilot to pave the way to a randomized controlled trial. Pilot Feasibility Stud. 2020 Oct 31;6(1):166. doi: 10.1186/s40814-020-00708-9.
- Ries JD, Hutson J, Maralit LA, Brown MB. Group Balance Training Specifically Designed for Individuals With Alzheimer Disease: Impact on Berg Balance Scale, Timed Up and Go, Gait Speed, and Mini-Mental Status Examination. J Geriatr Phys Ther. 2015 Oct-Dec;38(4):183-93. doi: 10.1519/JPT.0000000000000030.
- Amjad I, Toor H, Niazi IK, Pervaiz S, Jochumsen M, Shafique M, Haavik H, Ahmed T. Xbox 360 Kinect Cognitive Games Improve Slowness, Complexity of EEG, and Cognitive Functions in Subjects with Mild Cognitive Impairment: A Randomized Control Trial. Games Health J. 2019 Apr;8(2):144-152. doi: 10.1089/g4h.2018.0029. Epub 2018 Sep 21.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Anslået)
24. juni 2026
Primær færdiggørelse (Anslået)
15. juli 2026
Studieafslutning (Anslået)
15. august 2026
Datoer for studieregistrering
Først indsendt
23. juni 2026
Først indsendt, der opfyldte QC-kriterier
23. juni 2026
Først opslået (Faktiske)
29. juni 2026
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
29. juni 2026
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
23. juni 2026
Sidst verificeret
1. juni 2026
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 11691225SPREH (Anden identifikator: Ziauddin University)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
INGEN
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .